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Abstract
Following a request from European Commission, the Panel on Additives and Products or Substances
used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on the safety and efﬁcacy of
Robenz® 66G (robenidine hydrochloride (HCl)) when used as a feed additive for chickens for fattening
and turkeys for fattening. The coccidiostat Robenz® 66G is considered safe for chickens for fattening
at the highest proposed level of 36 mg robenidine HCl/kg complete feed with a margin of safety of
approximately 2.5. This conclusion is extrapolated to turkeys for fattening. Robenidine HCl is active
against Gram-positive but not against Gram-negative bacteria. It is not expected that the use of
robenidine HCl as a feed additive would induce resistance or cross-resistance to antimicrobials used in
human and animal therapy. The use of robenidine HCl from Robenz® 66G at the highest proposed
level of 36 mg/kg complete feed in chickens and turkeys for fattening is considered safe for the
consumer. The existing maximum residues limits for both avian species are conﬁrmed. Robenidine HCl
is not a skin or eye irritant and not a skin sensitiser. The risk via inhalation is considered negligible.
The use of robenidine HCl from Robenz® in feed for chickens for fattening and turkeys for fattening up
to 36 mg/kg complete feed does not pose a risk to either the terrestrial or the aquatic compartment. A
risk for bioaccumulation cannot be excluded. The risk for secondary poisoning is not likely to occur.
The FEEDAP Panel concludes that 36 mg robenidine HCl/kg complete feed from Robenz® 66G has the
potential to effectively control coccidiosis of chickens for fattening under ﬁeld conditions but cannot
conclude on the efﬁcacy of robenidine HCl in turkeys for fattening. The existing 5-day withdrawal
period to avoid off-ﬂavours in edible tissues should be maintained.
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of European Food Safety Authority.
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 10(2) of that Regulation also speciﬁes that for
existing products within the meaning of Article 10(1), an application shall be submitted in accordance
with Article 7, at the latest one year before the expiry date of the authorisation given pursuant to
Directive 70/524/EEC for additives with a limited authorisation period, and within a maximum of seven
years after the entry into force of this Regulation for additives authorised without a time limit or
pursuant to Directive 82/471/EEC.
The European Commission received a request from Zoetis Belgium SA2 for re-evaluation of the
product Robenz® 66G, robenidine hydrochloride, when used as a feed additive for chickens for
fattening and turkeys for fattening (category: coccidiostats and histomonostats).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
application to the European Food Safety Authority (EFSA) as an application under Article 10(2) (re-
evaluation of an authorised feed additive). EFSA received directly from the applicant the technical
dossier in support of this application. The particulars and documents in support of the application were
considered valid by EFSA as of 18 August 2014.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, consumer, user and the environment and on the efﬁcacy of the
product Robenz® 66G (robenidine hydrochloride), when used under the proposed conditions of use
(see Section 3.1.5).
1.2. Additional information
The additive Robenz® 66G was authorised in 2004 with the name Cycostat® 66G for use in
chickens for fattening and in turkeys for 10 years. The following maximum residue limits (MRL) are in
force for chickens for fattening (lg robenidine hydrochloride/kg wet tissue: 800 for liver, 350 for
kidney, 200 for muscle and 1,300 for skin fat) and for turkeys (lg robenidine hydrochloride/kg wet
tissue: 400 for liver, 200 for kidney, 200 for muscle and 400 for skin/fat).3 Robenz® 66G is also
authorised as a feed additive for rabbits for fattening and rabbits for breeding until 20 June 2021.4 The
withdrawal period is 5 days.
The Scientiﬁc Committee on Animal Nutrition (SCAN) issued an opinion on the use of robenidine in
feedingstuffs for rabbits (European Commission, 1982) and on the extension of the use of robenidine
in feedingstuffs for rabbits for breeding purposes (European Commission, 1995). In 2004, EFSA issued
two opinions on the re-evaluation of Cycostat® 66G in accordance with article 9G of Council Directive
70/524/EEC (EFSA, 2004a,b). In 2008, EFSA issued an opinion on MRLs and withdrawal period for
Cycostat® 66G for chickens and turkeys for fattening (EFSA, 2008a). In 2011, EFSA issued an opinion
on the re-evaluation of Cycostat® 66G for rabbits for fattening and breeding in accordance with
Regulation (EC) No 1831/2003 (EFSA FEEDAP Panel, 2011a).
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 Zoetis Belgium SA, Rue Laid Burniat 1, 1348, Louvain-la-Neuve, Belgium.
3 Commission Regulation (EC) No 1800/2004 of 15 October 2004 concerning the authorisation for 10 years of the additive
Cycostat 66G in feedingstuffs, belonging to the group of coccidiostats and other medicinal substances. OJ L 317, 16.10.2004,
p. 37. Amended by Commission Regulation (EC) No 101/2009 of 3 February 2009, OJ L 34, 4.2.2009, p. 5. (as regards MRLs);
amended by Commission Regulation (EC) No 214/2009 of 18 March 2009, OJ L 73, 19.3.2009. p. 12. (as regards the trade
name); amended by Commission Implementing Regulation (EU) No 118/2012 of 10 February 2012, OJ L 38 11.2.2012 p. 36.
(as regards the holder of authorisation); amended by Commission Implementing Regulation (EU) No 1014/2013 of 22 October
2013, OJ L 281, 23.10.2013. p. 1. (as regards the holder of authorisation).
4 Commission Implementing Regulation (EU) No 532/2011 of 31 May 2011 concerning the authorisation of robenidine
hydrochloride as a feed additive for rabbits for breeding and rabbits for fattening (holder of authorisation Alpharma Belgium
BVBA) and amending Regulations (EC) No 2430/1999 and (EC) No 1800/2004. OJ L 147, 1.6.2011. p. 7.
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2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier5 in support of the authorisation request for the use of Robenz® 66G (robenidine hydrochloride)
as a feed additive.
The FEEDAP Panel used the data provided by the applicant together with data from other sources,
such as previous risk assessments by EFSA or other expert bodies, peer-reviewed scientiﬁc papers and
other scientiﬁc reports and, to deliver the present output.
EFSA has veriﬁed the European Union Reference Laboratory (EURL) report as it relates to the
methods used for the control of the active substance in animal feed and marker residue in tissues. The
Executive Summary of the EURL report can be found in Annex A.6
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of Robenz® 66G
(robenidine hydrochloride) is in line with the principles laid down in Regulation (EC) No 429/20087 and
the relevant guidance documents: Guidance for the preparation of dossiers for coccidiostats and
histomonostats (EFSA FEEDAP Panel, 2011b), Technical guidance: Tolerance and efﬁcacy studies in
target animals (EFSA FEEDAP Panel, 2011c), Guidance on the assessment of the safety of feed
additives for the target species (EFSA FEEDAP Panel, 2017a), Technical Guidance for assessing the
safety of feed additives for the environment (EFSA, 2008b), Guidance for the preparation of dossiers
for the re-evaluation of certain additives already authorised under Directive 70/524/EEC (EFSA, 2008c),
Guidance for establishing the safety of additives for the consumer (EFSA FEEDAP Panel, 2012a),
Guidance on the assessment of the safety of feed additives for the consumer (EFSA FEEDAP Panel,
2017b), Guidance on studies concerning the safety of use of the additive for users/workers (EFSA
FEEDAP Panel, 2012b) and Technical Guidance: Microbial Studies (EFSA, 2008d).
3. Assessment
The current opinion is aimed at assessing the safety and efﬁcacy of the coccidiostat Robenz® 66G
(robenidine hydrochloride) when used as a feed additive for chickens for fattening and turkeys for
fattening.
3.1. Characterisation
3.1.1. Characterisation of the additive
Robenz® 66G contains the active substance robenidine hydrochloride (robenidine HCl) (6.6%), calcium
sulfate dihydrate (89.4%) and calcium lignosulfonate (4%). Analysis of ﬁve batches of Robenz® 66G
indicated product consistency; mean robenidine HCl content was 6.7% (range: 6.60–6.90%).8
Three batches of Robenz® 66G were analysed for content of ﬂuorine, arsenic, heavy metals, dioxins,
dioxin-like polychlorinated biphenyls (DL-PCBs) and non-DL PCBs and microbiological impurities.9 All
values were low and of no safety concern (ﬂuorine: 167–204 mg/kg, arsenic: 0.35–1.20 mg/kg, lead:
0.28–0.62 mg/kg, cadmium: 0.01 mg/kg, mercury: < 0.005 mg/kg; dioxins (polychlorinated dibenzo-p-
dioxins and dibenzofurans (PCDD/F)): 0.17–0.69 ng WHO-PCDD/F-TEQ/kg, the sum of dioxins and
DL-PCBs: 0.28–0.83 ng WHO-PCDD/F-PCB-TEQ/kg, non-DL PCBs: 0.002 mg/kg); Salmonella: absent in
25 g, Enterobacteriaceae: < 10 CFU/g, moulds: 300 CFU/g, yeasts: < 100 CFU/g, E. coli: < 10 CFU/g,
aerobic plate count: < 10 CFU/g coliforms: < 10 CFU/g and Staphylococcus aureus < 10 CFU/g).
5 FEED dossier reference: FAD-2013-0051.
6 The full report is available on the EURL website: https://ec.europa.eu/jrc/en/eurl/feed-additives/evaluation-reports/fad-2013-
0051
7 OJ L 133, 22.5.2008, p. 1.
8 Technical dossier/Section II/Annex II.1.3.2.
9 Technical dossier/Section II/Annex II.1.4.1.3, Annex II.1.4.1.4 and Annex II.1.4.1.5.
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Robenz® 66G is a greyish coloured free-ﬂowing granular preparation with a bulk density of
0.85 kg/L and a tapped density of 0.97 kg/L.10 Sieve analysis of three batches showed that >99% of
the product consists of particles between 150 and 850 lm.10 Only a minor fraction passes a 150-lm
mesh (≤ 0.40%). The dusting potential, measured in three batches (Stauber-Heubach), was calculated
to be 0.14 g/m3.11
3.1.2. Characterisation of the active substance
Robenidine hydrochloride (N1,N3-bis[(p-chlorobenzilidene)amino] guanidine hydrochloride; CAS
number: 25875-50-7) is a chemically synthesised substance. A minimum purity of 97% is speciﬁed by
the applicant. Its molecular formula is C15H13Cl2N5HCl; the molecular weight is 370.7 g/mol. Its
structural formula is given in Figure 1.
Robenidine HCl is a white-yellowish crystalline powder with a melting point of 288.4°C.12 Two major
impurities associated to the synthetic process have been identiﬁed as N,N’,N’’-tris[(p-chlorobenzylidene)
amino]guanidine (TRIS) and bis-(4-chlorobenzylidene)hydrazine (AZIN). The structural formula of these
compounds is given in Appendix A.
The applicant provided the following speciﬁcations: purity > 97%, TRIS ≤ 0.5%, AZIN ≤ 0.5%, any
individual unknown impurity ≤ 0.2% and sum of unknown impurities ≤ 1.0%. The analytical data were
in compliance with these speciﬁcations: analysis of three batches of robenidine HCl showed a mean
robenidine HCl concentration of 99.8%. Water content (loss on drying) was between 0.10% and
0.25%. The results for the impurities were: TRIS < 0.01%, AZIN < 0.02%, any individual unknown
impurity < 0.2% and the sum of unknown impurities < 0.2%.13 Additional data was provided on the
analysis of the impurities showing the same levels of AZIN (< 0.01%) and TRIS (0.02%); limit of
detection (LOD) and limit if quantiﬁcation (LOQ) were provided.14
3.1.3. Manufacturing process
Figure 1: Structural formula of robenidine hydrochloride
10 Technical dossier/Section II/Annex II.1.5.1.
11 Technical dossier/Section II/Annex II.1.5.3.
12 Technical dossier/Supplementary information April 2015/Annex 1.5.
13 Technical dossier/Section II/Annex II.1.3.4.
14 Technical dossier/Supplementary information April 2015/Annex 1.3; AZIN LOD: 0.01%, LOQ: 0.03%; TRIS LOD: 0.02%, LOQ:
0.06%.
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3.1.4. Stability and homogeneity
3.1.4.1. Shelf-life of the additive
Three batches of the additive were stored at 25°C/60% relative humidity (RH) for up to 36 months
and at 40°C/75% RH for six months.10 No signiﬁcant loss of robenidine HCl was observed after 36
months at 25°C/60% RH. Recovery of robenidine HCl at 40°C/75% RH was > 97% after three months
and 93% after six months.
3.1.4.2. Stability of the additive used in premixtures and feedingstuffs
The stability of Robenz® 66G in vitamin/mineral premixtures was determined in premixtures for
chickens for fattening (containing choline chloride) and for turkeys.20 Robenidine HCl inclusion level
was 6.6 g/kg. The premixtures were kept at 25°C/60% RH for up to 12 months and at 40°C/75% RH
for 3 months. Recovery of robenidine HCl after 12 months at 25°C was > 96%; after 3 months at 40°C
was > 90%.
In a second study, the stability of the additive incorporated into turkey complete feed at a level of
33 mg robenidine HCl/kg diet following pelleting at 80°C was studied.21 Pelleting did not inﬂuence the
robenidine HCl content. The pelleted feed was kept at 25°C for 3 months; the recovery was between
75 and 88%.
3.1.4.3. Homogeneity
Premixtures used for stability testing were analysed for homogeneity.20 The coefﬁcient of variation
(CV) of seven samples was 6.8% in the premixture for chickens for fattening and 4.7% in
the premixture for turkeys. Samples of mash turkey feed showed CVs from seven samples of
14.0–14.6%.21
In an additional study, homogeneity was studied in a premixture and in a feed for chickens for
fattening, mash and pelleted, (8 samples each) at target concentrations of 10 g robenidine HCl/kg and
33 mg robenidine HCl/kg, respectively.22 The CV in the premixture was 2.5%, in the mash feed 14.6%
and in the pelleted feed 6.0%.
3.1.5. Conditions of use
Robenz® 66G is a feed additive for the prevention of coccidiosis in chickens for fattening and
turkeys for fattening. The recommended feed inclusion level is 30 to 36 mg robenidine HCl/kg
complete feed, with a 5-day withdrawal period.
3.2. Safety
3.2.1. Absorption, distribution, metabolism, excretion and residues
3.2.1.1. Absorption, distribution, metabolism, and excretion
No new studies have been submitted. The applicant made reference to the studies on the
metabolic fate of robenidine HCl in chicken, turkeys and laboratory animals already assessed by
the FEEDAP Panel in its previous opinions (EFSA 2004a, 2008a). The FEEDAP Panel considered that
the data from those studies are still relevant for the current assessment and the same conclusions can
be retained:
1) Robenidine HCl is absorbed at a limited extent and excreted rapidly by the chicken and
turkey
2) Robenidine main metabolic pathways in chicken and turkey involve the hydrolysis of the
semi-carbazide bonds of the molecule, followed by the oxidation of the resulting p-
chlorobenzaldehyde to p-chlorobenzoic acid. Conjugation of p-chlorobenzoic acid with lysine
or ornithine and formation of mixed conjugates with exogenous benzoic acid and
hydroxybenzoic acid occur. In the chicken, the cyclisation of the aminoguanidine moeity of
robenidine leads to a triazole derivative. No signiﬁcant gender difference was observed
20 Technical dossier/Section II/Annex II.4.1.2.
21 Technical dossier/Section II/Annex II.4.1.3.
22 Technical dossier/Section II/Annex II.4.2.1.
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3) Unchanged robenidine is the major compound (40–80%) excreted by the chicken and turkey,
all the metabolites accounting each less than 10% of the whole robenidine-related
compounds excreted
4) Robenidine represents also the major identiﬁed residue (marker residue) in chicken and
turkey, metabolites accounting for less than 10% each. The liver is the target tissue
5) The metabolic fate of robenidine in the rat is qualitatively very similar to that in the chicken
and turkey, the only difference relating to the nature of the amino acids involved in the
conjugation of p-chlorobenzoic acid. Moreover, very small quantities of the triazole cyclic
metabolite identiﬁed in the chicken have been found in the fat of the rat.
A literature review made by the applicant23 did not identify any relevant paper for the current
assessment (Appendix B).
3.2.1.2. Residue studies
No new study has been submitted. The applicant made reference to the total and marker residue
studies in chickens and turkeys which were evaluated by the FEEDAP Panel in 2008 (EFSA, 2008a).
The FEEDAP Panel considers that the data from those studies are still valid for the current assessment.
An overview of the relevant data is given below.
Robenidine-derived total residues in chicken and turkey tissues were evaluated in studies following
a similar protocol in which birds (three males and three females) were administered 36 mg
radiolabelled robenidine HCl/kg feed until study state and slaughtered at 0-, 1- and 3-day withdrawal
times (Table 1).
Total residues in all relevant tissues are higher in chicken compared to turkey. Considering the
given physiological proximity of chicken and turkey and the similar qualitative metabolic fate of
robenidine in both species, the assessment for turkeys can rely on the chicken data (EFSA, 2008a).
In the same study, robenidine residues were also determined in chicken and turkey tissues
(Table 2).
Table 1: Kinetics of robenidine-derived total residues in tissues of chickens (average of three males
and three females  standard deviation) and turkeys (average of three males and three
females  standard deviation) administered 36 mg radiolabelled robenidine HCl/kg feed
until steady state and slaughtered at different withdrawal times (expressed as mg
robenidine equivalents/kg wet tissue)
Withdrawal (days) Liver Kidney Skin/fat Muscle
Chicken 0 2.516  0.732 0.885  0.251 1.372  0.364 0.169  0.043
1 1.569  0.468 0.540  0.131 0.821  0.349 0.070  0.025
3 0.633  0.137 0.161  0.024 0.211  0.042 0.007  0.004
Turkeys 0 1.610  0.332 0.570  0.052 0.829  0.126 0.065  0.012
1 0.814  0.282 0.279  0.099 0.389  0.214 0.023  0.013
3 0.498  0.082 0.145  0.024 0.250  0.072 0.010  0.003
Table 2: Kinetics of robenidine residues in chicken and turkey tissues (average of three males and
three females) administered 36 mg radiolabelled robenidine HCl/kg feed until steady state
and slaughtered at different withdrawal times (expressed as mg robenidine/kg wet tissue)
Withdrawal (days) Liver Kidney Muscle Skin/fat
Chicken 0(1) 0.507 0.229 0.060 0.823
1(2) 0.232 0.134 < LOQ 0.420
3(2) < LOQ < LOQ < LOQ < LOQ
Turkeys 0(1) 0.261 0.030 0.006 0.257
1(2) 0.131 < LOQ < LOQ 0.197
(1): Determined by radio-HPLC; average values from pooled samples (males and females separately).
(2): Determined by HPLC in individual samples; average values, LOQ = 0.1 mg/kg for all tissues.
23 Technical dossier/Supplementary information April 2015. Databases searched: Medline, Embase, Biosis, CAB Abstracts,
Derwent Veterinary Drug File, Agricola, Pascal, Toxcenter, SciSearch, Chemical Abstracts, Dissertation Abstracts and ProQuest
SciTech Collection. Period: 2004–2015.
Robenz® 66G (robenidine hydrochloride) for chickens for fattening and turkeys for fattening
www.efsa.europa.eu/efsajournal 8 EFSA Journal 2019;17(3):5613
Marker residue concentrations in all tissues were higher in the chicken compared to turkey after
0- and 1-day withdrawal.
3.2.2. Safety for the target species
3.2.2.1. Tolerance study in chickens for fattening
A total of 600 one-day old Ross 708 chickens (300 males and 300 females) were randomised into
ﬁve treatment groups which were fed diets containing 0, 33 (19 the recommended level), 49.5
(1.59), 66 (29) and 82.5 (2.59) mg robenidine HCl/kg complete feed (analytically conﬁrmed),
respectively, for 35 days.24 Group size was 120 birds per treatment (6 replicates for each gender with
10 birds each). The basal diet consisted mainly of maize and methionine supplemented soybean meal;
the starter formulation was calculated to contain 21.7% crude protein (CP), 3.8% crude fat (CF) and
0.59% methionine; the grower formulation 20.0% CP, 4.1% CF and 0.55% methionine. The starter
was fed as crumbles for 21 days, the grower as pellets until the end of the study. The birds had
ad libitum access to the feed. Clinical examination was performed twice daily and measurements of
individual body weight and feed consumption were performed weekly. Blood samples were taken for
haematology25 and clinical biochemistry26 from one animal per pen on day 35. The same animals were
killed, necropsied and tissue samples27 were collected. Histopathology was performed on the organs
collected from the control and the high-dose group (and on any abnormal tissues from other animals).
Statistical evaluation was done by a general linear mixed model (GLMM) with the ﬁxed effects of
treatment, sex, and interaction treatment 9 sex. The pen was considered the statistical unit;
differences were considered signiﬁcant at a level of p < 0.1 (two-sided).
A total of six birds died during the course of the study. The main results are summarised in Table 3.
There were no signiﬁcant differences in ﬁnal body weight, average daily gain, or feed intake
between treatments or at any time point during the course of the study. There were no signiﬁcant
differences observed in feed to gain ratio for the overall period.
There were no biologically relevant treatment-related effects during hematologic evaluation. The
only signiﬁcant differences found in haematology were males of the use level group had a signiﬁcantly
higher monocyte value (1.17 9 103/lL) than males of all other groups (0.27–0.70 9 103/lL). Males at
the 1.59 level group had a signiﬁcantly lower monocyte value (0.27) compared to the 2.59 level
group (0.7 9 103/lL). There were no treatment-related ﬁndings for clinical chemistry parameters
except serum calcium (slightly decreased levels in males of groups 19 and 1.59 compared to controls)
and serum phosphorus (slightly increased in combined male and female birds of groups 19 and 29
compared to controls). These ﬁndings are not considered treatment-related because they were not
observed in higher dose groups, and had no associated morphologic changes.
Table 3: Main results of a 35-day tolerance study in chickens for fattening with Robenz® 66G
Robenidine HCl
(mg/kg feed)
Average feed intake
(g/bird per day)
Final bw (g) Feed to gain ratio Mortality (n)(1)
0 79 1899 1.46 2
33 77 1874 1.45 2
49.5 79 1888 1.46 0
66 79 1893 1.45 1
82.5 77 1867 1.45 3
(1): Including culls.
24 Technical dossier/Supplementary information June 2016.
25 Red blood cell count (RBC), haematocrit, mean corpuscular haemoglobin (MCH), red cell distribution width (RDW),
thrombocyte check, heterophils, lympocytes, haemoglobin, mean corpuscular volume (MCV), mean corpuscular haemoglobin
concentration (MCHC), white blood cell count (WBC) and differentials, eosinophils, basophils, monocytes.
26 Aspartate aminotransferase (AST), alkaline phosphatase, creatine kinase, total protein, total cholesterol, blood urea nitrogen
(BUN), glucose, calcium, phosphorus, sodium, potassium, chloride, uric acid, alanine aminotransferase (ALT), lactate
dehydrogenase (LDH), gamma-glutamyl transpetidase (GGT), magnesium.
27 The following samples were collected, weighed, and placed into 10% buffered neutral formalin: liver; heart; spleen; kidneys;
and bursa of Fabricius. The following samples were collected and placed into formalin without being weighed: crop; gizzard;
small intestine (duodenum with pancreas, jejunum and ileum); caecum; proventriculus; and skeletal muscle.
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There were no treatment-related effects on organ weights. Kidney weights (absolute and relative to
body weight) were statistically increased over control birds for females in groups 19 and 1.59, and for
males in group 19. These changes were not considered treatment-related because there were no
microscopical changes associated.
There were no treatment-related ﬁndings during gross pathology including microscopy. Gross
pathology and microscopic ﬁndings were considered incidental, of the nature commonly observed in
this breed and age of chicken and/or were of similar incidence in the control and treated animals.
Conclusions on the tolerance study in chickens for fattening
The tolerance study in chickens for fattening did not identify signiﬁcant differences of the treated
groups to the untreated control group for the performance parameters, for haematology, blood
biochemistry and gross pathology and microscopy. Small, however, signiﬁcant differences, in plasma
calcium and phosphorus, as well as in kidney weight, were not treatment related. The FEEDAP Panel
concludes therefore that the minimum use level (33 mg robenidine HCl/kg feed) is safe for chickens
for fattening with a margin of safety of 2.5. However, the highest applied robenidine concentration is
36 mg/kg feed. Considering study design with the use of 1.5-, 2- and 2.5-fold of the use level and the
observed margin of safety, the Panel does not see any concern to extend its conclusion on the safety
of robenidine HCl for chickens for fattening to 36 mg/kg complete feed.
3.2.2.2. Tolerance study in turkeys for fattening
As the margin of safety of Robenz® 66G in chickens for fattening is approximately 2.5, the FEEDAP
Panel considers that the conclusion reached in the tolerance study in chickens for fattening can be
extrapolated to turkeys for fattening at the same dose (EFSA FEEDAP Panel, 2017a). Supporting
evidence of this conclusion is provided by a tolerance study in turkeys for fattening. The study, which
showed several limitations, is described below.
A total of 80 one-day-old BUT 10 turkeys (40 males and 40 females) were randomised into four
treatment groups which were fed diets containing 0, 36 (19 the maximum recommended level), 108
(39) and 180 (59) mg robenidine HCl/kg complete feed (analytically conﬁrmed), respectively, for 56
days.28 Group size was 20 birds per treatment (2 replicates for each gender with 5 birds each). The
basal diet consisted mainly of wheat, maize and extracted soya; no information on the CP, CF and
methionine content was provided. Starter and grower diets were offered as pellets for ad libitum
access, the starter for the ﬁrst 2 weeks, followed by the grower diet until study completion. Clinical
examination, measurements of individual body weight, feed and water consumption were performed
weekly. Cumulative data for feed intake were not submitted, feed to gain ratio was not calculated.
Blood samples were taken for haematology29 and clinical biochemistry30 on two animals per pen on
day 56. The same animals were killed, necropsied and organ samples31 were collected. Histopathology
was performed on the tissues collected from the control and the high-dose group (and on any
abnormal tissues from other animals).
Statistical evaluation was done not considering the pen as the experimental unit. It was done by a
GLMM with ﬁxed effects of treatment, sex, and interaction treatment 9 sex. Differences were
considered signiﬁcant at a level of p < 0.1 (two-sided).
During the study, no mortalities or treatment-related clinical signs were seen as well as no
signiﬁcant differences in ﬁnal body weight of turkeys were observed (4,673, 4,514, 4,488 and 4,743 g
in the four experimental groups, respectively). Cumulative data for feed intake were not submitted;
feed to gain ratio was not calculated.
Leucocyte, heterophile lymphocyte counts were signiﬁcantly lower in the high-dose robenidine
group compared to the control group (12.4 vs 6.7, 6.18 vs 3.54 and 5.54 vs 2.81 9 109, respectively).
28 Technical dossier/Section III/Annex III.1.1.
29 Red blood cell count (RBC), haemoglobin concentration, haematocrit, mean corpuscular volume (MCV), mean corpuscular
haemoglobin concentration (MCHC), mean corpuscular haemoglobin (MCH), total leucocyte count (WBC) monocyte count,
heterophil count, eosinophil count, basophils count, lymphocyte count.
30 Sodium, potassium, chloride, calcium, phosphate, magnesium, total protein, albumin, globulin, glucose, uric acid, cholesterol,
amylase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), alkaline
phosphatase (ALP), creatine kinase, glutamate dehydrogenase (GLDH).
31 The following samples were collected, weighed and placed into 10% buffered neutral formalin: liver, heart, spleen, kidneys;
the following samples were collected and placed into formalin without being weighed: thyroid, adrenal glands, pancreas,
spinal cord, eyes, lung, trachea, skeletal muscle, brain, skin, bone and marrow, bursa of Fabricius and thymus, gall bladder,
proventriculus, ventriculus, duodenum, jejunum, ileum, colon, caecum; testes and epididymis, entire length of oviducts,
uterus, ovaries.
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Another small signiﬁcant difference was found for aspartate aminotransferase (AST) for the high-dose
robenidine group (59) compared to the control group, (259 vs 298 IU/L).
No signiﬁcant differences between the organ weights relative to body weight were observed, as
well as no speciﬁc macroscopic/microscopic ﬁndings were noted.
Overall, the study design (insufﬁcient number of replicates per treatment and gender, pen not used
as experimental unit) and reporting (no data for cumulative feed intake/bird and feed to gain ratio) do
not allow the FEEDAP Panel to derive any conclusion on the safety of robenidine HCl in turkeys from
zootechnical data. However, it is noted that haematology indicated treatment-related effects of the
ﬁvefold overdose (signiﬁcant reduction of leucocyte, heterophile and lymphocyte counts). No other
relevant and treatment-related signiﬁcant adverse effects were seen in clinical biochemistry, necropsy
and histopathology. No adverse ﬁndings were described for the robendine HCl use level and its
threefold concentration.
Conclusions on the tolerance study in turkeys for fattening
As the margin of safety of Robenz® 66G in chickens for fattening is approximately 2.5, the FEEDAP
Panel considers that the conclusion reached in the tolerance study in chickens for fattening can be
extrapolated to turkeys for fattening at the same dose. Therefore, the FEEDAP Panel concludes that
Robenz® 66G is safe for turkeys for fattening at 36 mg/kg complete feed.
3.2.2.3. Interactions
In its opinion in 2011 (EFSA FEEDAP Panel, 2011a), the FEEDAP Panel concluded that ‘No
interactions or incompatibilities with feed materials, carriers, other approved additives or veterinary
drugs have been recorded or reported’.
No relevant papers were found in the target species by the literature search performed by the
applicant (Appendix B).23
In line with former conclusions, no interactions or incompatibilities with feed materials, carriers,
other approved additives or veterinary drugs are expected when Robenz® 66G is used as a feed
additive for chickens and turkeys for fattening.
3.2.2.4. Microbial studies
The microbiological safety of robenidine HCl was already assessed by the FEEDAP Panel in 2004
and 2011 (EFSA, 2004a,b, EFSA FEEDAP Panel, 2011a). For the current assessment, the applicant
made reference to the studies previously assessed and performed a literature review covering the
period 2004–2015; a total of ﬁve publications were found; none of them was considered relevant for
the current assessment.23
In the absence of new data the FEEDAP Panel reiterates its previous conclusion:
‘Robenidine is active against Gram-positive but not against Gram-negative bacteria. Gram positive
bacteria are susceptible at concentrations relevant for the in vivo situation, considering the
proposed dose range’.
The literature review did not identify publications regarding the effect of robenidine HCl on the
development of resistance in vitro and in vivo and on cross-resistance to other antimicrobials.
Moreover, considering also the mode of action, it is not expected that the use of robenidine HCl as a
feed additive would induce resistance or cross-resistance to antimicrobials used in human and animal
therapy.
The literature review did not report studies on the effect of robenidine on the increase of shedding
or colonisation of enteropathogens. However, it cannot be excluded that the use of robenidine HCl as a
feed additive may increase shedding of enteropathogenes.
3.2.2.5. Conclusions on the safety for the target species
The FEEDAP Panel concludes that the use of Robenz® 66G at the concentration of 36 mg
robenidine HCl/kg feed is safe for chickens for fattening with a margin of safety of approximately 2.5.
This conclusion is extrapolated to turkeys for fattening.
No interactions or incompatibilities are expected when Robenz® 66G is used as a feed additive for
chickens and turkeys for fattening.
Robenidine is active against Gram-positive but not against Gram-negative bacteria. It is not
expected that the use of robenidine HCl as a feed additive would induce resistance or cross-resistance
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to antimicrobials used in human and animal therapy; it cannot be excluded that the use of robenidine
HCl as a feed additive may increase shedding of enteropathogenes.
3.2.3. Safety for the consumer
3.2.3.1. Toxicological studies
The toxicological proﬁle of robenidine HCl was already assessed by the FEEDAP Panel in 2004 and
2011 (EFSA, 2004a,b; EFSA FEEDAP Panel, 2011a). For the current assessment, the applicant made
reference to the toxicological studies previously assessed and performed a literature review covering
the last 10 years (until 2015).23
The FEEDAP Panel re-assessed the toxicological studies available in the context of previous
submissions (EFSA, 2004a,b; EFSA FEEDAP Panel, 2011a). The main results can be summarised as
follows.
Genotoxicity of robenidine HCl was tested in studies performed according to the relevant OECD
guidances. It gave negative results in a bacterial reverse mutation assay, was not clastogenic in
cultured mammalian cells and did not induce micronuclei in the bone marrow of treated mice.
Therefore, robenidine HCl can be considered as not genotoxic.
Subchronic studies (90 days) were performed in rats, mice and dogs. In the rat study (performed in
1968), no substance-related changes were observed and a no observed adverse effect level (NOAEL)
of 13.5 mg/kg body weight (bw) per day, based on the highest dose in males, has been identiﬁed. A
NOAEL of 14 mg/kg bw per day in mice was proposed (study performed in 1968) based on renal
changes (focal nephritis) seen at the dose of 28 mg/kg bw per day (EFSA, 2004a,b; EFSA FEEDAP
Panel, 2011a). A re-evaluation of the 90-day dog study (performed in 1968) showed that the original
robenidine HCl concentrations were given in mg/kg feed. The lowest no observed effect level (NOEL)
in this study was recalculated to be 19 mg/kg bw per day derived from the data on the increase in
relative liver weight observed at the dose of 34 mg/kg bw per day (EFSA FEEDAP Panel, 2011a). The
recalculated NOAEL resulted to be about 2.5 times higher than the value the FEEDAP Panel calculated
in 2004 (EFSA, 2004a,b). In a 90-day Good Laboratory Practice (GLP)-compliant rat study performed
according to OECD 408, no treatment-related changes were observed at the mid-dose of 37 mg/kg bw
per day and this dose was considered as the NOAEL of the study (EFSA FEEDAP Panel, 2011a).
Two chronic studies were conducted in rats and dogs. In the rat study, no tumour developments or
preneoplastic lesions were observed; in the dog study, tumour developments were not recorded. The
Panel noted that the studies had some limitation in their design. However, the lack of genotoxic
potential considered alongside the absence of any ﬁndings of pre-carcinogenic lesions in toxicological
studies supports the conclusion that robenidine HCl is not carcinogenic (EFSA, 2004a,b; EFSA FEEDAP
Panel, 2011a).
No negative maternal effects or effects on litters by the treatment were seen at any stage of a
reproduction study in rabbits; no treatment-related teratogenic effects or inﬂuence on reproduction
were observed at any stage of a two-generation study in rats on females, or on litters and fetuses; the
maternal and fetal NOAEL in a developmental toxicity study in rabbits was 20 mg robenidine HCl/kg
bw per day.
In its opinion in 2011, the FEEDAP Panel noted that the NOAELs of the available 90-day studies are
in a narrow range: 13.5 and 37 mg robenidine HCl/kg bw per day in the rat, 14 mg/kg bw per day in
mice and 19 mg/kg bw per day in dogs. In the same opinion, the Panel evaluated a tolerance study in
rabbits performed in line with the requirements of Regulation (EC) No 429/20087 and concluded that
the study was adequate to derive a NOAEL, considering also that study duration (84 days) was
comparable with the 90-day studies in rodents and the dog. The NOAEL of 11 mg robenidine HCl/kg
bw per day was taken from the study based on the absence of reproductive effects.
Considering that the literature review performed by the applicant covering the last 10 years (until
2015)32 did not identify any new data that would require modiﬁcation of the previous assessment
(Appendix B), the lowest NOAEL of 11 mg robenidine HCl/kg bw per day from the tolerance study in
rabbits is still considered adequate for the establishment of a health-based guidance value for the
assessment of consumer safety.
32 Technical dossier/Supplementary information April 2015. Databases searched: Medline, Embase, Biosis, CAB Abstracts,
Derwent Veterinary Drug File, Agricola, Pascal, Toxcenter, SciSearch, Chemical Abstracts, Dissertation Abstracts and ProQuest
SciTech Collection.
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3.2.3.2. Assessment of consumer safety
In its former assessment of robenidine HCl (EFSA FEEDAP Panel, 2011a), the FEEDAP
Panel proposed a health-based guidance value (acceptable daily intake (ADI)) of 0.11 mg robenidine
HCl/kg bw, equivalent to 6.6 mg/day for a 60-kg adult, based on the lowest NOAEL of 11 mg
robenidine HCl/kg bw day derived from a rabbit tolerance study, applying a uncertainty factor of 100.
The Panel noted that the uncertainty factor used for the derivation of the ADI in 2011 needs to be
updated to 200, according to the principles set in the Guidance on selected default values to be used
by the EFSA Scientiﬁc Committee, Scientiﬁc Panels and Units in the absence of actual measured data
(EFSA Scientiﬁc Committee, 2012). The recalculated ADI used for the assessment of consumer safety
is therefore 0.055 mg robenidine HCl/kg bw (corresponding to 3.3 mg/day for a 60-kg adult).
Daily exposure of consumer to robenidine total residues resulting from the consumption of chicken
tissues was recalculated according to the daily food consumption values of animal products set in
Regulation (EC) No 429/20087, using the data given above at 0-day withdrawal (see Section 3.2.1.2).
The results are reported in Table 4.
The exposure represents 20% of the health-based guidance value. The contribution of total
robenidine residues in edible tissues of chicken to 20% of the ADI is based on the food basket of the
Regulation (EC) No 429/2008. Applying instead European food consumption data from EFSA’s
Comprehensive European Food Consumption Database (see Guidance on the assessment of the safety
of feed additives for the consumer (EFSA FEEDAP Panel, 2017b)), this contribution would account only
to about 6% of the ADI. As far as total residues in turkey tissues at 0-day withdrawal are lower than in
the chicken, the results of the calculation made for chicken tissues would also apply to turkey residues.
Therefore, the FEEDAP Panel reiterates its previous conclusions that no risk is expected from the
consumption of tissues from chickens and turkeys fed robenidine HCl at the maximum recommended
level without withdrawal period.
Commission Regulation (EC) No 101/200933 established the following MRLs (on a wet tissue basis)
for chickens for fattening: 800 lg robenidine hydrochloride/kg liver, 350 lg/kg kidney, 200 lg/kg
muscle and 1,300 lg/kg skin fat. Dietary intake calculated from these MRLs would represent 64% of
the ADI. The same Regulation established the following MRLs for turkeys: 400 lg robenidine
hydrochloride/kg liver, 200 lg/kg kidney, 200 lg/kg muscle and 400 lg/kg skin fat. Dietary intake
calculated from these MRLs would represent 32% of the ADI.
In Commission Regulation (EC) No 101/200933, a 5-day withdrawal period is speciﬁed to avoid off-
ﬂavours in edible tissues from poultry treated with robenidine HCl at 36 mg/kg complete feed.
In the absence of new data, the same withdrawal period should be maintained (see Section 3.3.3.).
3.2.3.3. Conclusions on safety for the consumer
The use of robenidine HCl from Robenz® 66G at the highest proposed level of 36 mg/kg complete
feed in chickens for fattening and turkeys for fattening is considered safe for the consumer.
Table 4: Consumer theoretical exposure to robenidine total residue concentrations (TRCs) in
chickens administered Robenz® 66G at a dose corresponding to 36 mg robenidine/kg feed
at 0-day withdrawal
Liver Kidney Muscle Skin/fat Sum
TRC + 2SD(1) 3.980 1.387 0.285 2.100
Consumption (g/day)(2) 100 10 300 90 500
DITR (mg/day)(3) 0.398 0.014 0.086 0.189
% ADI 12 0.4 2 6 20.4
(1): TRC: total residue concentration (average) + 2 standard deviations.
(2): Based on the food basket of Regulation (EC) No 429/2008.
(3): Dietary intake calculated from total residues.
33 OJ L 34, 4.2.2009, p. 5.
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3.2.4. Safety for the user
No new data have been submitted by the applicant.
The same studies, assessed in former opinions (EFSA, 2004a, 2008a), were re-submitted by the
applicant and re-assessed by the FEEDAP Panel.
In a 4-hour acute inhalation study in rats conducted in 1999 according to GLPs with the active
substance robenidine HCl, the FEEDAP Panel noted that the inhalation LC50 was > 5.2 mg/L (EFSA,
2004a).
Skin and eye irritation studies were conducted in 1968 with the active substance robenidine HCl
and with a formulation containing 10% of robenidine HCl. A sensitisation study was performed with
robenidine HCl according to OECD Guideline 406 and GLP. The FEEDAP Panel could conﬁrm that the
studies provided evidence that robenidine HCl is not a skin or eye irritant and not a skin sensitiser.
The FEEDAP Panel reviewed the information on the physical properties of the additive. Robenz®
66G is a granular product with only a minor fraction of particles smaller than 150 lm (≤ 0.40%) and
with a low dusting potential (0.14 g/m3); therefore, exposure of users/workers handling Robenz® 66G
would be very low.
The literature search provided by the applicant covering the last 10 years (until 2015) did not
reveal any new data relevant to user safety (Appendix B).23
The FEEDAP Panel reiterates its previous conclusions that robenidine HCl is not a skin or eye irritant
and not a skin sensitiser. Based on the low acute inhalation toxicity and low exposure, the risk via
inhalation is considered negligible.
3.2.5. Safety for the environment
The active substance is not a physiological/natural substance of established safety for the
environment. Consequently, according to Regulation (EC) No 429/20087 the Phase I assessment has to
be continued to determine the predicted environmental concentration (PEC).
In Phase I, a total residues approach will be taken meaning that the predicted environmental
concentrations will be calculated based on the assumption that the additive is excreted 100% as
parent compound.
The applicant submitted the same studies assessed by the FEEDAP Panel in its opinion on the
safety and efﬁcacy of Cycostat® 66G (robenidine HCl) for rabbits for breeding and fattening (EFSA
FEEDAP Panel, 2011a) and, upon request, performed a literature review covering the last 10 years
(until 2015).34
3.2.5.1. Phase I
The physico-chemical properties of robenidine HCl are summarised in Table 5.35 The vapour
pressure of robenidine HCl was not provided.
Robenidine HCl is protonated at acidic pH and not charged at pH 7. The physico-chemical
properties of neutral form (robenidine) are relevant for the environmental risk assessment. The
FEEDAP Panel noted that the solubility of the neutral molecule was not provided. The solubility of the
Table 5: Physico-chemical properties of robenidine HCl
Property Value Unit
Molecular weight 370.7 G/mol
Octanol/water partition coefﬁcient (log Kow) by HPLC method (OECD 117) 3.3 –
Octanol/water partition coefﬁcient (log Kow) by Shake ﬂask method (pH = 7)
(OECD 107)
4.7(1)
Solubility at 20°C (pH around 3.5) 118 mg/L
Dissociation constant pKa 3.4 –
Vapour pressure Not provided Pa
(1): Based on the solubility of robenidine HCl in buffer solution at pH 7 and in octanol, a log Kow of 2.9 and 4.7 could be
determined. However, as the recovery of the item in the test system was below 90%, the latest value has been taken as a
reasonable worst-case estimate.
34 Technical dossier/Supplementary information April 2015. Period: 2004–2015.
35 Technical dossier/Section III/Annex 4.12.
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neutral form of robenidine was estimated using EPI Suite to be 4.877 mg/L and the vapour pressure
was estimated to be 1.22 E-06 Pa. These values were used for the calculation of the PECs since the
applicant did not provide relevant data.
The FEEDAP Panel noted that the log Kow for robenidine HCl has been determined according to
both OECD guideline 117 (high-performance liquid chromatography (HPLC) method) and 107 (shake
ﬂask method), (EFSA FEEDAP Panel 2011a). Based on the HPLC method, the log Kow of robenidine HCl
is 3.3. The shake ﬂask method was performed at pH 2.3, 7 and 9.8. At pH 2.3, a log Kow value of 2.5
was determined. At pH 7 and 9, difﬁculties arose due to the low solubility and maintenance of the pH
at the desired level. Based on the solubility of robenidine HCl in the buffer solution at pH 7 and in the
octanol, a log Kow of 2.9 and 4.7 could be determined. However, as the recovery of the item in the
test system was below 90%, the latest value has been taken as a reasonable worst case estimate for
the assessment of secondary poisoning.
Fate and behaviour
Fate in soil
Degradation in soil
The degradation of robenidine HCl was already assessed by the FEEDAP Panel in its opinion in 2011
(EFSA FEEDAP Panel, 2011a) as follow: ‘A study on the transformation of robenidine HCl performed in
three types of soil gave DT50 values for robenidine HCl of 12 and six days for sandy loam (pH 6.5,
1.4% organic carbon, 17.2% clay) and clay loam (pH 7.2, 1.5% organic carbon, 31.7% clay) and 162
days for loamy sand (pH 3.5, 1.1% organic carbon, 3.4% clay). The extraction efﬁciency was low in
particular for loamy sand: 13%. The fast degradation in sandy loam and clay loam was mainly based
on a formation of unknown component B and accounted for a maximum of 24% of the applied
radioactivity after 32 days in extracts of sandy loam. It was postulated that this compound was formed
by re-arrangement of the parent compound, tentatively named 3-amino-4-(p-chlorobenzylideneamino)-
5-(p-chlorophenyl)-4H-1,2,4-triazole (using the naming tool in ACD/Chemsketch, see Figure 2). The
DT50 values for component B were estimated to be 138 and 97 (average 118 days) days for sandy
loam and clay loam, respectively.
The reason for the difference in degradation rate observed between loamy sand and the other two soil
types might be the form in which the substance is present. The pH of loamy sand is low at which the
compound will be protonated which hamper the re-arrangement of the parent compound. In the two
soils the compound will be present in the non-ionized form. As a pH of 3.5 is not considered to be relevant
for agricultural soils, the DT50 value measured in loamy sand is not considered in this risk assessment’.
The FEEDAP Panel agreed to use the same DT50 of 118 days at 20°C. This value corresponds to
251 days when it is adjusted to an incubation temperature of 12°C using the Arrhenius equation (DT90
> 1 year).36
Adsorption/desorption in soil
The adsorption of robenidine HCl was already assessed by the FEEDAP Panel in its opinion
published in 2011 (EFSA FEEDAP Panel, 2011a).
The FEEDAP Panel re-assessed the studies available and noted that the applicant claimed that they
could not perform a sorption study according to OECD 106 due to the rapid transformation of
robenidine HCl; this might have been caused by the low pH of a solution of robenidine HCl in 10 mM
Figure 2: Proposed structure of the major degradation product formed in soil
36 The temperature correction was performed according to the scientiﬁc opinion of the Panel on Plant Protection Products and
their Residues on a request from EFSA related to the default Q10 value used to describe the temperature effect on
transformation rates of pesticides in soil (EFSA, 2007).
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CaCl2. The applicant performed also an HPLC study according to OECD 121 at pH 2.5 and 6
(dichlorodiphenyltrichloroethane (DDT) being the reference standard). Since the pKa of robenidine is
3.4, it can be expected that the cationic form is present at pH 2.5 and the neutral form at pH 6. At pH
6, HPLC analysis resulted in the elution of two components indicating that robenidine was partly
converted into a degradation product. An attempt was made to identify this product by repeating the
sorption study under dark and daylight conditions. It appears that the peak of the degradation product
was only observed under daylight conditions, suggesting that the formation of the unknown peak is a
photolytic reaction. The transformation of robenidine HCl by photolysis is conﬁrmed by Hansen et al.
(2009). Several attempts were made to elucidate the structure of the second peak, but these were
unsuccessful. It was demonstrated that in a methanol and ethanol buffer solution, the second peak
occurred as well. Such a degradation process was previously observed and the resulting product was
characterised as 3-amino-4-(p-chlorobenzylideneamino)-5-(p-chlorophenyl)-4H-1,2,4-triazole (EFSA
FEEDAP Panel, 2011a), which is the same structure as proposed for the major metabolite observed in
the soil transformation study. Although the precise identity is still not conﬁrmed, it is considered very
likely that the major metabolite formed in soil and the second peak observed in the sorption study are
identical compounds and have the same adsorption behaviour.
Both the parent robenidine and the degradation product eluted slower than the reference
compound DDT. Therefore, the assumption of the applicant that the sorption of robenidine HCl was
stronger than that of DDT (Koc = 426,580) was followed by the Panel.
Fate in water
The rate of hydrolysis of robenidine HCl was already assessed by the FEEDAP Panel in its opinion
published in 2011 (EFSA FEEDAP Panel, 2011a) and it was noted that the rate of hydrolysis was tested
at pH 4, 7 and 9.16. The FEEDAP Panel reiterates its previous conclusions that robenidine HCl is
hydrolytically stable at pH 7 and 9, but shows hydrolysis at more acidic conditions (pH 4).
Conclusion on fate and behaviour
The Koc of 426,580 L/kg is used for the further risk assessment.
Taking a conservative approach, the FEEDAP Panel selected a DT50 of 251 days for robenidine HCl
derived from a transformation product.
Predicted environmental concentrations
PECs were calculated according to the FEEDAP technical guidance for assessing the safety of feed
additives for the environment (EFSA, 2008b) and are given in Table 6.
The Phase I PEC trigger values were exceeded. Therefore, a Phase II assessment is considered
necessary.
Table 6: Initial predicted environmental concentrations (PECs) of robenidine HCl in soil (lg/kg),
groundwater (lg/L), surface water (lg/L) and sediment (lg/kg dry weight)
Input Value
Dose (mg/kg feed) 36
Molecular weight (g/mol) 370.7
Vapour Pressure (Pa) 1E-06
Solubility (mg/L) 4.877
Koc (L/kg) 426,580
Output Chickens for fattening Turkeys for fattening
PECsoil 187 167
PECgroundwater 0.025 0.022
PECsurfacewater 0.008 0.007
PECsediment 177 158
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3.2.5.2. Phase II
Exposure assessment
PECs calculation reﬁned in Phase II
Studies on the excretion of robenidine HCl and its metabolites in the environment were assessed by
the FEEDAP Panel in 2011 (EFSA FEEDAP Panel, 2011a). The results of the studies indicated that in
the chicken, unchanged robenidine amounted to 44% (male) and 34% (female) of the radioactivity
excreted; up to nine metabolites were separated but not identiﬁed, each amounting to less than 10%.
In the turkey, robenidine represented 52% (male) and 44% (female) of the radioactivity excreted
while eight metabolites (not identiﬁed) represented less than 10%, each. Based on the lack of data on
the toxicological potential of robenidine metabolites on the environment, the impact of the metabolites
cannot be discarded from the assessment. A prudent approach was retained considering the whole
robenidine-derived metabolites in excreta as toxicologically relevant.
According to EFSA guidance (EFSA, 2008b), if a high persistence in soil is anticipated (DT90 > 1
year), the potential for residues to accumulate in soil should be considered. This is the case for
robenidine HCl. The input values used for the reﬁned PEC calculations based on persistence were the
same indicated in Table 6; a DT50 251 days (at 12°C) was used. The calculated values are given in
Table 7.
Conclusions on PECs used for assessment
The following values are used for the assessment in chickens for fattening and turkey (worst case
approach): a PECsoil of 294 lg/kg, a PECsurface water of 0.013 lg/L and a PECsediment of 278 lg/kg dry
weight. No concern is expected for groundwater.
Ecotoxicity studies
Effects on plants
The effect of robenidine HCl on plants was already assessed by the FEEDAP Panel in its opinion
published in 2011 (EFSA FEEDAP Panel, 2011a) as follows: ‘Effect of robenidine hydrochloride on the
emergence and growth of seedlings of wheat (Triticum aestivum), radish (Raphanus sativus) and
mung bean (Phaseolus aereus) was studied in sandy loam soil (pH 5.6, organic carbon 0.4%, organic
matter 0.7%) according to OECD guideline 208. Emergence and growth rate of all three plants species
showed no reduction at the maximum concentration tested (EC50 and NOEC > 100 mg/kg)’.
The FEEDAP Panel re-assessed the study and reiterates its previous conclusions.
Effect on earthworms
The acute effect of robenidine HCl in earthworms was already assessed by the FEEDAP Panel in its
opinion published in 2011 (EFSA FEEDAP Panel, 2011a) as follows: ‘The acute toxicity to earthworms is
determined in a 14-day test. No mortality was observed at the maximum concentration tested
(LC50 > 1,000 mg/kg). A signiﬁcant difference in mean weight change was reported at all doses. In
fact, the control animals showed a higher reduction in body weight than the treated animals. After 14
days the mean body weight of all treated animals differed not more than 5% from the control animals.
The pH in the soil was 6  0.5, therefore, values should refer to the non-ionised compound’.
The FEEDAP Panel re-assessed the study and reiterates its previous conclusions.
Nitrogen Transformation
The effects of robenidine HCl on soil microorganisms were already assessed by the FEEDAP Panel in
its opinion published in 2011 (EFSA FEEDAP Panel, 2011a) as follows: ‘Effects on soil micro-organisms
Table 7: Predicted environmental concentrations of robenidine HCl in soil (lg/kg), groundwater (lg/L),
surface water (lg/L) and sediment (lg/kg dry weight) reﬁned for persistent compounds
Compartment Chickens for fattening Turkeys
PECsoil 294 263
PECgroundwater 0.039 0.035
PECsurfacewater 0.013 0.012
PECsediment 278 248
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were studied on nitriﬁcation and nitrogen mineralization in sandy loam soil (pH 6.5, organic carbon
1.3%, total nitrogen 1526 mg/kg, 40% maximum water holding capacity) at concentrations of 0.36
and 1.8 mg/kg. After 28 days no effects were observed at the maximum concentration tested (NOEC
> 1.8 mg/kg). No information on the toxicity of degradation compound B is provided. Expecting that
the degradation pathway observed in the soil biodegradation study also takes place in the soils used to
investigate the toxicity to earthworms, plants and micro-organisms, it is assumed that the test
organisms are also exposed to this compound’.
The FEEDAP Panel re-assessed the study and reiterates its previous conclusions.
Toxicity to aquatic organisms
The acute toxicity of robenidine to algae, daphnids and ﬁsh were already assessed by the FEEDAP
Panel in its opinion published in 2011 (EFSA FEEDAP Panel, 2011a). In 2011, the FEEDAP Panel noted
that: ‘Acute toxicity to algae, daphnids and ﬁsh has been determined according to the current OECD
standards. Due to the relatively low solubility of robenidine hydrochloride in water, difﬁculties were
encountered during the preparation of test concentrations in all three acute toxicity studies conducted
with aquatic organisms. Furthermore, the test item tended to adsorb onto surfaces of materials used
in the studies. Therefore, supersaturated suspensions of the test item were prepared and ﬁltrated, and
the ﬁltrate plus dilutions thereof were used in the studies. Concentrations of robenidine hydrochloride
were measured prior to test start, at deﬁned time points during the study and at the end of the test.
Results were reported as overall mean measured concentrations (average over all measurements per
test concentration)’.
The FEEDAP Panel re-assessed the studies and for the current assessment will follow the same
approach.
Effects on algae
The effect of robenidine HCl on the green algal species Scenedesmus subspicatus was investigated
in a 72-h GLP study following the OECD 201 guidelines. During the test, the concentration of the test
item declined; therefore, the average measured values of 0.009, 0.011, 0.026 and 0.069 mg/L were
considered for the calculation of the effect of the tested substance on algae. The test meets the
validity criteria resulting in inhibitory effect on the growth rate at 72-h ErC50 of 0.067 mg/L and NOEC
of 0.026 mg/L.
Effects on crustaceans
The acute toxicity of robenidine HCl on the crustacean species Daphnia magna was investigated in
a 48-h static test according to the OECD Guideline 202 (1984). The 10-fold dilution series were
prepared (1:2.2–1:22). The results on acute effect of the robenidine HCl were related to the total
mean measured test substance concentrations (calculated as the average over all measurements per
test concentration) which were 0.037 mg/L (dilution 1:2.2) and 0.082 mg/L (undiluted ﬁltrate). The
acute effect concentration of the robenidine HCl was determined as 48-h EC50 with the value of
0.061 mg/L.
Effects on ﬁsh
The acute toxicity of robenidine HCl on zebra ﬁsh Brachydanio rerio was investigated in a study
following OECD Guideline 203 (1992). In the 96-h, test the 10–fold series were prepared (1:2.2–1:22).
Results are related to the total mean measured test item concentrations (calculated as the average
over all measurements per test concentration) which were 0.019 mg/L (dilution 1:4.6), 0.067 mg/L
(dilution 1:2.2) and 0.18 mg/L (undiluted ﬁltrate). The acute effect concentration of the robenidine HCl
was determined as 96-h EC50 with the value of 0.036 mg/L.
The data showed that robenidine HCl is highly toxic to aquatic organisms. The following EC50
values have been determined (Table 8).
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As the pH of all three studies was between 7.7 and 8.0, robenidine HCl was present in the non-
ionised form.
Effect on sediment dwelling organisms
The toxicity of robenidine HCl to Chironomus riparius was already assessed by the FEEDAP Panel in
its opinion published in 2011 (EFSA FEEDAP Panel, 2011a) as follows: ‘The toxicity of robenidine
hydrochloride to Chironomus riparius was investigated using spiked sediment in accordance to OECD
218. First instar larvae were exposed to concentrations ranging from 6.25 to 100 mg/kg dry sediment.
The pH of the overlying water varied between 7.7 and 8.3. The test item was almost completely found
in the sediment, conﬁrming the strong adsorption of robenidine hydrochloride to sediment particles at
environmentally relevant pH. The NOEC was 50 mg/kg based on both emergence and development
rate’.
The FEEDAP Panel re-assessed the study and reiterates its previous conclusions.
Conclusions on the ecotoxic effect on soil, water and sediment
For the terrestrial compartment, data are available for plants, earthworms and microorganisms.
Acute toxic concentrations resulted in 1,000 and 100 mg/kg of dry soil for earthworms and plants,
respectively. For the aquatic compartment, data are available for algae, aquatic invertebrates and ﬁsh.
The lowest toxicity value of 96-h EC50 of 36 lg/L for the aquatic compartment was found in a study on
the effect on ﬁsh. Nevertheless, considering the very low solubility of the substance at neutral pH, the
values obtained are uncertain.
Ecotoxicological data for sediment-dwelling invertebrate Chironomus riparius is provided for the
sediment compartment resulting in NOEC of 50 mg/kg.
Risk characterisation (PEC/PNEC ratio)
Robenidine HCl emissions into the environment are higher when it is used in the feed for chicken
for fattening than in turkeys for fattening. Therefore, the environmental risk assessment is based on
use of this active ingredient in chickens. The risk characterisation ratios for terrestrial, freshwater and
sediment compartments when the manure is incorporated into the soil are reported in the tables below
(Tables 9, 10 and 11).
Table 8: Acute toxic effects of robenidine HCl to aquatic organisms
Species EC50 values (lg/L)
Scenedesmus subspicatus 67 (based on growth rate)(1)
Daphnia magna 61(2)
Brachydanio rerio 36(3)
(1): 72-h ErC50.
(2): 48-h EC50.
(3): 96-h EC50.
Table 9: Risk characterisation (PEC/PNEC ratio) of robenidine HCl for terrestrial compartment
Taxa PECsoil (lg/kg) LC50/EC50/NOEC (mg/kg) AF PNEC (lg/kg) PEC/PNEC
Earthworm 294 1,000(1) 1,000 1,000 0.3
Plants 100(2) 100 1,000 0.3
AF: assessment factor.
(1): LC50.
(2): EC50 and NOEC.
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Considering the very low PEC/PNEC ratio (four orders of magnitude < 1), even if there are
uncertainties in the results of the acute toxicity test, the FEEDAP Panel considers that there is an
acceptable risk for surface water.
Bioaccumulation and secondary poisoning
Based on log Kow of 4.7, robenidine HCl has a potential for bioaccumulation. In order to assess the
risk for secondary poisoning, the method according the EU Technical Guidance Document for new and
existing substances has been considered (EMA, 2016). Using the lowest NOEC for birds of 225 mg/kg
feed, adopted by the FEEDAP Panel in 2004 (EFSA, 2004a), the PNEC oral is 7.5 mg/kg. This value is
higher than the estimated concentration in the worms and ﬁsh of 0.051 and 0.051 mg/kg, respectively,
which are based on PECs presented in Table 7. Hence, a risk for secondary poisoning for worm/ﬁsh-
eating birds and mammals is not likely to occur.
3.2.5.3. Conclusions on safety for the environment
The use of robenidine HCl from Robenz® in feed for chickens for fattening and turkeys for fattening
up to 36 mg/kg complete feed does not pose a risk to either the terrestrial or the aquatic
compartment. No concern is expected for groundwater. A risk for bioaccumulation cannot be excluded.
The risk for secondary poisoning is not likely to occur.
The literature search provided by the applicant on robenidine HCl did not reveal any new data
relevant to the safety for the environment.
3.3. Efﬁcacy
For coccidiostats under re-evaluation, efﬁcacy data should derive from two types of target animal
experiments: (a) natural/artiﬁcial infection to simulate use conditions (e.g., ﬂoor pen studies with
poultry), at least one of the locations should be in the EU, (b) actual use conditions in ﬁeld trials, all
should be done in the EU within the last ﬁve years. Anticoccidial sensitivity tests (ASTs) could replace
Table 10: Risk characterisation (PEC/PNEC ratio) of robenidine HCl for freshwater compartment
Taxa
PECsurfacewater
(lg/L)
72-h ErC50/48-h EC50/96-h
EC50 (lg/L)
AF
PNEC
(lg/L)
PEC/
PNEC
Algae(1)
Pseudokirchneriella
subcapitata
0.013 67(1) 1,000 36 0.0004
Aquatic invertebrates
Daphnia magna
acute
61(2)
Fish
Brachydanio rerio
36(3)
AF: assessment factor.
(1): 72-h ErC50.
(2): 48-h EC50.
(3): 96-h EC50.
Table 11: Risk characterisation (PEC/PNEC ratio) of robenidine HCl for sediment
Taxa
PECsediment
(lg/kg)
NOEC
(mg/kg)
AF
PNEC
(lg/kg)
PEC/PNEC
Sediment-dwelling invertebrates
Chironomus riparius
278 50 10 5,000 0.06
AF: assessment factor.
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ﬁeld trials provided they follow the criteria mentioned in the guidance document on coccidiostats and
histomonostats (EFSA FEEDAP Panel, 2011b).37
3.3.1. Efﬁcacy in chickens for fattening
3.3.1.1. Floor pen studies
Three ﬂoor pen studies were submitted.38 One-day-old birds (male Ross 308, male Ross PM3 and
male/female of a slowly growing strain ISA JA 757 in trials 1, 2 and 3, respectively) were penned and
distributed into treatment groups as indicated in Table 12. Treated groups received feed with an
intended concentration of 33, 30 and 30 mg robenidine HCl/kg feed in trials 1, 2 and 3, respectively.
The target concentrations were analytically conﬁrmed in trials 2 and 3, while in trial 1 only 84% of the
intended concentration could be measured (see Table 12). Infected groups were inoculated with ﬁeld
isolates of pathogenic Eimeria species (see Table 13 for details). Animal health and mortality were
monitored daily. Feed intake and body weight of the animals were measured throughout the study,
feed to gain ratio was calculated. Samples of excreta were analysed for oocyst excretion and intestinal
lesions were scored on ﬁve birds per pen following the method of Johnson and Reid (1970) (0 = no
lesion, 1 = very mild, 2 = mild, 3 = moderate and 4 = severe).
The pen was the experimental unit for statistical purposes. In trial 1, all parameters were analysed
by multifactorial analysis of variance (ANOVA), group means were compared by least signiﬁcant
difference (LSD) test. In trial 2, data were statistically analysed by one-way ANOVA; group differences
for the zootechnical endpoints were examined by Tukey test and for lesion scores by Newman–Keuls
test. Statistical analysis in trial 3 was done by GLMM. Mortality, oocyst counts per gram (OPG) and
lesion scores were analysed for normal distribution by the Kolmogorov–Smirnov test and as data
showed to be not normally distributed, the parameters were subjected to the Kruskal–Wallis test and
the Mann–Whitney U-test.
Table 12: Experimental design of ﬂoor pen studies performed with Robenz® 66G
Trial
Study
duration(1)
(days)
Replicates
per
treatment
(birds per
replicate)
Treatment groups
Intended
concentration of
robenidine HCl
(mg/kg feed)
Analysed
robenidine
HCl(2)
(mg/kg
feed)
1 41 8 (40) Uninfected untreated control group
(UUC)
– –
Infected untreated control group (IUC) – –
Infected treated group (IT) 33 27.3/28
2 36 8 (90) Infected untreated control group (IUC) – –
Infected treated group (IT) 30 31/32
3 42 8 (30) Infected untreated control group (IUC) – –
Infected treated group (IT) 30 31.4/27.4
(1): Supplemented feed was administered until day 36 in trial 1 and until day 31 in trial 2.
(2): The two values correspond to the two different diets administered in the ﬁrst and second half of the study.
37 The FEEDAP Panel stated in its guidance for the preparation of dossiers for coccidiostats and histomonostats (EFSA FEEDAP
Panel, 2011b) that studies with artiﬁcial infection would be preferred over ﬁeld trials due to their inherent weaknesses. These
short term studies should use ﬁeld strains of Eimeria, recently conﬁrmed as pathogenic/resistant by a sensitivity test or
recognised problems in the poultry operation (conﬁrmed by veterinary certiﬁcate). The Eimeria ﬁeld strains should ideally
undergo one, but in any case not more than two passage(s) before use in such trials.
38 Trial 1: Technical dossier/Section IV/Annex IV.3.1; Trial 2: Technical dossier/Section IV/Annex IV.3.2; Trial 3: Technical dossier/
Section IV/Annex IV.3.3.
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Mortality after inoculation in trial 1 was low (between 2 and 7 birds per group) and in no case
coccidiosis related. In trial 2, coccidiosis-related mortality was found in the week following inoculation
(1 in IUC and 3 in IT), but the difference was not signiﬁcant. In trial 3, overall mortality was very low
(6 from 480) and coccidiosis-related mortality amounted to 1 bird only in the IUC group.
In trial 1, the Eimeria-speciﬁc lesion scores (due to E. acervulina, E. maxima and E. tenella) about
1 week after inoculation were signiﬁcantly reduced by the treatment compared to IUC. No signiﬁcant
effect was seen 1 week later (Table 14).
In trial 2, lesion scores in the duodenum and jejunum–ileum were signiﬁcantly reduced by the
treatment one week after inoculation but not in the subsequent week (Table 15).
In trial 3, inoculation with pathogenic Eimeria species resulted 6 and 8 days after inoculation in
intestinal lesion scores between 0.5 and 2.0 for the different intestinal regions of the IUC group
(Table 16). No lesions were found in the IT group.
Table 13: Summary of inoculation in ﬂoor pen studies performed with Robenz® 66G
Trial Start date
Inoculum characteristics
Month/year and
country of isolation
Intended dose per bird Day and mode of inoculation
1 4/2007 Belgium 217,000 E. acervulina Day 15 via feed
24,800 E. tenella
8,300 E. maxima
2 5/2011 6/2009
Ireland
250,000 E. acervulina Day 17 via feed
28,450 E. maxima
3 5/2011 2/2010
The Netherlands
2.2 9 105 E. acervulina Day 13 via feed
1.5 9 104 E. maxima
2.0 9 104 E. tenella
Table 14: Eimeria species-speciﬁc lesion scores in trial 1
E. acervulina E. maxima E. tenella Total
Day 22 Day 29 Day 22 Day 29 Day 22 Day 29 Day 22 Day 29
UUC 0.07a 0.80 0.30a 0.45 0.05a 0.20 0.42a 1.45
IUC 1.40c 0.42 0.92b 0.27 1.45b 0.10 3.77b 0.80
IT 0.62b 0.62 0.30a 0.42 0.27a 0.15 1.20a 1.20
a,b,c,: Means in a column with different superscript are signiﬁcantly different (p ≤ 0.05).
Table 15: Mean lesion scores in different intestinal regions in trial 2
Duodenum Jejunum-ileum Caecum
Day 24 Day 31 Day 24 Day 31 Day 24 Day 31
IUC 2.59 0.88 1.64 1.50 0 0.48
IT 1.95* 0.65 1.15* 1.35 0 0.30
Mean values with * are signiﬁcantly different from IUC (p ≤ 0.05).
Table 16: Mean lesion scores in different intestinal regions in trial 3
Upper intestine Middle intestine Caecum
Day 19 Day 21 Day 19 Day 21 Day 19 Day 21
IUC 1.0 1.0 0.5 1.0 2.0 1.0
IT 0* 0* 0* 0* 0* 0*
Mean values with * are signiﬁcantly different from IUC (p ≤ 0.001).
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A reduction of oocyst excretion by the treatment with robenidine HCl was seen in all trials. It was
signiﬁcant in trial 1 one week after inoculation but not later (2 and 3 weeks after inoculation). It was
also signiﬁcant in trial 2 one week after inoculation (and three weeks after inoculation), OPG values 11
and 14 days after inoculation were not different between IUC and IT. In trial 3, oocyst excretion was
signiﬁcantly reduced by the treatment at several days after inoculation (Table 17).
The use of robenidine HCl resulted also in a statistical improvement of feed intake and body weight/
gain in trials 1 and 2 and of feed to gain ratio in trial 1. No such effect was seen in trial 3 (Table 18). The
performance of the birds was in all trials in compliance with the performance objectives of the breeds.
3.3.1.2. Field trials
One ﬁeld trial was submitted in which 8,000 one-day-old female Ross 308 chickens for fattening
were randomly allocated to two different rooms with 4,000 birds each and fed the experimental diet
for 37 days followed by a withdrawal period of 5 days.39 The two diets were supplemented with either
robenidine HCl from Robenz® 66G (target concentration 33 mg/kg; analysed concentration 45.8, 39.8
and 37.1 mg/kg feed in starter, grower and ﬁnisher feed, respectively) or an ionophore coccidiostat
(target concentration 7 mg/kg).
Overall mortality was high; with 10.4% in the robenidine group and 12.2% in the ionophore group. At
the end of the study, body weight of the robenidine group was signiﬁcantly higher than that of the ionophore
group (2,458 vs. 2,308 g) with a tendency (not signiﬁcant) for a better feed to gain ratio (1.79 vs. 2.00).
Table 17: Total number of Eimeria oocysts per gram of excreta (OPG) in ﬂoor pen studies
Trial 1 Day 22 Day 29 Day 36
UUC 412a 12,975 4,375
IUC 78,812b 26,225 2,612
IT 38,812ab 23,610 1,587
Trial 2 Day 24 Day 24
E. maxima
Day 28 Day 28
E. maxima
Day 31 Day 31
E. maxima
Day 36 Day 36
E. maxima
IUC 904,350 10,350 136,650 2,000 3,825 25 8,750 138
IT 367,700* 12,200 120,550 550* 4,038 50 40,900* 763
Trial 3 Day 18 Day 21 Day 24 Day 27 Day 30 Day 33 Day 36 Day 42
IUC 23,250 76,025 70,700 125,250 4,200 1,800 50 0
IT 425* 10,550* 3,050* 33,500 325* 0* 0 0
a,b,c: Means in a column with different superscript are signiﬁcantly different (p ≤ 0.05).
Mean values with * are signiﬁcantly different from IUC (p ≤ 0.05).
Table 18: Performance data of chickens in ﬂoor pen trials with Robenz® 66G
Feed Intake (g/day) Final body weight (g) Weight Gain(1) (g) Feed to gain ratio
Trial 1
UUC 106.4a 2,748a 66.1a 1.61ab
IUC 102.9b 2,633b 63.3b 1.63b
IT 105.6a 2,773a 66.7a 1.58a
Trial 2
IUC 84.2 1,983 – 1.55
IT 87.1* 2,053* – 1.55
Trial 3
IUC – – 987 3.83
IT – – 1,021 3.61
–: not reported.
a,b,c: Means in a column within a trial with different superscript are signiﬁcantly different (p ≤ 0.05).
Mean values with * are signiﬁcantly different from IUC (p ≤ 0.05).
(1): Results of trial 1 refer to daily gain; results of trial 3 refer to total body weight gain.
39 Technical dossier/Section IV/Annex IV.3.7.
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Faecal samples from each group were collected on days 14, 21, 28, 35 and 42. No oocysts were
found in any of the examined samples. Consequently no intestinal lesions related to coccidiosis were
found when examined on six birds per group on days 21 and 28.
Since no Eimeria infection could be shown, the ﬁeld trial could not be accepted for the
demonstration of efﬁcacy of robenidine HCl.
3.3.1.3. Anticoccidial sensitivity tests
Four anticoccidial tests were submitted. One of the ASTs could not be used for the demonstration
of efﬁcacy since the infection level was too low as indicated by the very low intestinal lesion scores.40
The other three studies are described below.41
The tests were made with the groups UUC, IUC and IT, the latter receiving feed supplemented with
intended concentrations of 36, 33 and 36 mg robenidine HCl/kg feed in AST-1, AST-2 and AST-3,
respectively. The analysed values were 36, 35 and 37.2 mg robenidine HCl/kg feed.
Male Ross PM3 chickens were used in AST-1 and AST-2 and male and female Ross 308 in AST-3.
The 1-day-old birds were fed the basal diet until day 13 and then randomly allocated to the groups
with the supplemented diets. Group size was 18 chickens (3 replicates with 6 birds) in AST-1 and AST-
2, and 120 chickens (10 replicates with 12 birds) in AST-3. Birds were artiﬁcially infected with
sporulated oocysts from ﬁeld isolates on day 15 in AST-1 and AST-2 and on day 13 in AST-3.42
Endpoints were: mortality, oocyst excretion, intestinal lesions (lesion score scale ranging from 0 to 4
was applied according to the method of Johnson and Reid, 1970), body weight gain, feed consumption
and feed to gain ratio. The observational period was 1 week after infection.
Statistical analysis was based on ANOVA using general linear models (GLM) procedure. In AST-1
and AST-2, intestinal lesion scores were analysed by Kruskal–Wallis test and the differences between
groups were assessed using the Newman–Keuls test.
There was no coccidiosis-related mortality in any of the studies.
The results of the similar studies AST-1 and AST-2 are summarised in Table 19. The data show that
36 mg (analysed) robenidine HCl/kg complete feed reduced the E. maxima-related lesion score
signiﬁcantly but not that related to E. acervulina in AST-1. In AST-2, the E. acervulina-related lesion
score was signiﬁcantly reduced by 35 mg (analysed) robenidine HCl/kg feed but not that related to
E. maxima and E. tenella. The total oocyst excretion was not positively affected by the treatment. The
excretion of E. maxima oocysts was signiﬁcantly lower in the robenidine groups of both ASTs. The
infection signiﬁcantly affected the parameters of body weight and feed to gain ratio (only in AST-2),
the treatment with robenidine HCl resulted in a partial compensation.
Table 19: Results of AST-1 and AST-2
Tr.
group
Feed
intake
(g/day)
Body
weight
(g)
Weight
gain (g)
Feed to
gain
ratio
Mean lesion scores OE 3 106(1)
E.
acervulina
E.
maxima
E.
tenella
Total
E.
maxima
D13–22 D22 D13–22 D13–22 D22 D20–22
AST-1 UUC 104.2 1,040.6a 66.0a 1.59b 0.0b 0.0c  0c 0b
IUC 87.8 817.5c 39.5b 2.24a 3.7a 2.8a  210b 8a
IT 101.1 919.4b 52.5b 1.93a 3.2a 1.1b  385a 0b
AST-2 UUC 90.3 1,035a 65.9a 1.37c 0.0c 0.0b 0.0b 0b 0c
IUC 76.8 780.7c 37.2c 2.07a 3.2a 2.1a 3.3a 646a 6.2a
IT 86.1 876.5b 49.2b 1.76b 1.9b 1.4a 2.3a 475a 0.4b
a,b,c: Means in columns within a study with different superscript are signiﬁcantly different (p ≤ 0.05).
(1): OE: oocyst excretion/bird and day. Figures were calculated from the droppings sampled per cage in 24 hrs and divided by
the number of birds in the respective cage.
40 Technical dossier/Supplementary information February 2017/Annex 1.
41 AST-1: Technical dossier/Section IV/Annex IV.2.1. (2009) AST-2: Technical dossier/Section IV/Annex IV.2.2. (2011) AST-3:
Technical dossier/Supplementary information August 2017/Annex 1. (2017).
42 AST 1: Polish ﬁeld isolate (2009); estimated dosage per bird: 335,000 sporulated oocysts (288,750 E. acervulina, 46,250
E. maxima); AST 2: Belgian ﬁeld isolate (2010); estimated dose per bird: 273,100 sporulated oocysts (245,000 E. acervulina +
2,500 E. maxima + 25,600 E. tenella); AST-3: Belgian ﬁeld isolate (2017); estimated dose per bird was 220,000 sporulated
oocysts (138,000 E. acervulina, 60,000 E. tenella, 4,000 E. maxima and 18,000 E. mitis).
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The results of AST-3 with 37 mg (analysed) robenidine HCl/kg feed are summarised in Tables 20
and 21. Only E. tenella-related lesion scores were signiﬁcantly reduced by the treatment, whereas
E. tenella speciﬁc oocyst excretion was only numerically lower than in IUC. A signiﬁcant reduction of
OPG was observed with E. maxima oocysts. The zootechnical parameters were signiﬁcantly reduced by
the infection in AST-3 and the reduction was compensated by the treatment.
Conclusions of efﬁcacy in chickens for fattening
In the three ﬂoor pen studies made with 33, 30 and 30 mg robenidine HCl/kg feed, a signiﬁcant
reduction of oocyst excretion and of intestinal lesion scores was seen in the treated groups in all
studies. The three ASTs made with 36, 33 and 36 mg robenidine HCl/kg feed showed some
improvements of intestinal lesion scores and oocyst excretion. The intestinal lesion score was reduced
in AST-1 against E. maxima, in AST-2 against E. acervulina and in AST-3 against E. acervulina and
tenella; in all ASTs E. maxima, E. acervulina and E. tenella were examined. In AST-1 and AST-2, total
oocyst excretion was reduced, in AST-3 only that of E. maxima (of a total of four Eimeria species
examined). These ﬁndings together allow the FEEDAP Panel to conclude on a potential of the additive
to control coccidiosis under ﬁeld conditions. However, considering the robenidine HCl concentrations
applied in the six studies, a coccidiostatic effect of robenidine in chickens for fattening was
demonstrated at the inclusion level of 36 mg/kg complete feed.
3.3.2. Efﬁcacy in turkeys for fattening
3.3.2.1. Floor pen studies
Three ﬂoor pen studies in turkeys for fattening, conducted in 2012, were submitted.43 The studies
followed the same design. One-day-old birds (BUT5, Aviagen Big 6 and BUT male turkeys for fattening
in studies 1, 2 and 3, respectively) were penned and distributed into four treatment groups: an UUC
group, an IUC group, an uninfected treated (UT) group and IT group. The IT group received feed at an
intended concentration of 30 mg robenidine HCl/kg feed (see Table 22). Group size was 60 turkeys
(6 replicates with 10 birds). Infected groups were inoculated on day 14 with recent ﬁeld isolates of
pathogenic Eimeria species via a syringe.44 Diets were fed in three or four phases to all treatment
groups as detailed in Table 22. Animal health and mortality were monitored daily. Feed intake and body
Table 20: Results of coccidiosis-related endpoints in AST-3
Tr. group
Mean lesion scores OPG
E. acer E. max E. ten Total E. acer E. max E. ten E. mit
D20 D13–20
UUC 0.6c 0.2b 0.1b 10,019b 7,822b 3c 31b 50b
IUC 1.4b 0.7a 1.0a 364,547a 202,870a 61,909a 22,344a 7,512a
IT 1.9a 0.5a 0.1b 315,676a 282,394a 5,369b 2,523a 8,092a
E. acer: Eimeria acervulina; E. maxima: Eimeria maxima; E. ten: Eimeria tenella; E. mit: Eimeria mitis.
a,b,c: Means in columns within a study with different superscript are signiﬁcantly different (p ≤ 0.05).
Table 21: Results of performance in AST-3
Tr. group Feed intake (g/day) Weight gain (g) Feed to gain ratio
UUC 91.7a 68.1a 1.35c
IUC 76.0c 47.3c 1.61a
IT 84.1b 57.4b 1.47b
a,b,c: Means in columns within a study with different superscript are signiﬁcantly different (p ≤ 0.05).
43 Trial 1: Technical dossier/Section IV/Annex IV.3.4; Trial 2: Technical dossier/Section IV/Annex IV.3.5; Trial 3: Technical dossier/
Section IV/Annex IV.3.6.
44 Trial 1: Belgium ﬁeld isolate (07/2011); estimated dosage per bird: 117,000 E. meleagrimitis, 48,000 E. adenoeides, 4,000
E. dispersa; Trial 2: German ﬁeld isolate (08/2011); estimated dose per bird: 8,300 E. meleagrimitis, 1,400 E. adenoeides, 300
E. dispersa; Trial 3: French ﬁeld isolate (07/2011); estimated dose per bird was 18,000 E. meleagrimitis, 9,340 E. adenoeides,
1,840 E. dispersa.
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weight of the animals were measured throughout the study, feed to gain ratio was calculated. Samples
of excreta were analysed for oocyst excretion and intestinal lesions were scored on one bird per pen on
days 21, 28 and 35 following the method of Johnson and Reid (1970) (0 = no lesion, 1 = very mild,
2 = mild, 3 = moderate and 4 = severe). Trials lasted 112 days followed by 5-day withdrawal period.
Statistical analyses were conducted at the 0.05 level of signiﬁcance using two-sided tests. Body
weight and oocyst counts were analysed with a general linear repeated measures mixed model. Feed
consumption, feed to gain ratio and mortality were analysed with GLMMs. Intestinal lesion scores were
analysed using Fisher’s Exact test.
Mortality after inoculation in trial 1 was low and there were no statistically signiﬁcant differences
among the treatments (Table 23). No information was provided on the cause of the deaths. In trials 2
and 3 mortality was high. In trial 2, no explanation was provided for the high mortality reaching in an
average of the UUC and UT groups about 18%. For this reason, this trial could not be further
considered for the evaluation of efﬁcacy. In trial 3, the high mortality rates were due to a bacterial
infection at the beginning of the study. All birds received antibiotic treatment from day 5 to day 10.
Due to the high mortality rate and the concurrent medication, this trial could not be further considered
for the evaluation of efﬁcacy.
In trial 1, there were no signiﬁcant differences between groups IUC and IT in the percentage of
birds with abnormal lesion scores (i.e. lesion scores other than 0) seen in the lower small intestine and
in caecum on days 21, 28 and 35.
A reduction of oocyst excretion by the treatment with robenidine HCl was seen in trial 1. It became
signiﬁcant 3 weeks after inoculation (day 35) (Table 23).
Performance parameters were not signiﬁcantly affected by the treatment (mean body weight 12.3
kg, mean feed to gain ratio 2.33).
Table 22: Experimental diets fed to turkeys for fattening in the ﬂoor pen studies
Trial
Diet(1)
Type Period (days)
Feed analysis
(mg/kg feed)
robenidine HCl
1 Starter 0–28 22.9
Grower 1 28–56 30
Grower 2 56–84 24.8
Finisher 84–112 20.3
2 Starter 0–28 27
Grower 1 28–78 28
Grower 2 78–112 33/34
3 Starter 0–28 30
Grower 1 28–56 24.4
Grower 2 56–84 27
Finisher 84–112 27
(1): Birds in the UT and IT groups were fed a basal diet supplemented with Robenz® 66G. Animals in the UUC and IUC groups
received the same basal diet without inclusion of the coccidiostat.
Table 23: Total number of Eimeria oocysts per gram of excreta (OPG) in ﬂoor pen trial 1
Trial 1 Day 21 Day 28 Day 35 Day 42 Day 49 Day 56 Day 63 Day 70
UUC 0 0 3 149 1,532 1,424 164 22
IUC 10,539 3,182 809 358 6 9 2 2
UT 0 0 0 12 1 8,203 127 20
IT 5,453 1,659 116* 4* 0* 10 2 3
*: IT signiﬁcantly different from IUC mean (p ≤ 0.05).
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3.3.2.2. Anticoccidial sensitivity tests
Three ASTs with a similar experimental design, performed in 2013, were submitted.45 Each test was
made with the groups UUC, IUC and IT. The IT group received feed supplemented with Robenz® 66G
at an intended concentration of 36 mg robenidine HCl/kg feed (analysed concentrations: 40, 34 and 38
mg robenidine HCl/kg feed in the three tests, respectively). In each test, one-day-old male turkeys for
fattening (Big 6 is AST-1 and AST-2, Converter in AST-3) were randomly allocated to the experimental
groups on day 10 (AST-1 and AST-2) and 12 (AST-3). Group size was 30 birds (5 replicates with 6
birds). Birds were artiﬁcially infected on study day 14 (AST-1 and AST-2) or 16 (AST-3) with sporulated
oocysts from ﬁeld isolates.46 The experiment lasted for a total of 21 days (AST-1 and AST-2) or 23
days (AST-3). Animal health and mortality were monitored. Feed intake and body weight of the
animals were measured, feed to gain ratio was calculated. Samples of excreta were analysed for
oocyst excretion. Intestinal lesions were scored following the method of Johnson and Reid (1970)
(0 = no lesion, 1 = very mild, 2 = mild, 3 = moderate and 4 = severe).
Body weight and oocyst counts were analysed with a general linear repeated measured mixed
model with ﬁxed effects (treatment, time point and treatment by time point) and random effects
(block, and block by treatment). Feed consumption, feed to gain ratio and lesions scores were
analysed with a GLMM with the ﬁxed effect of treatment and the random effect of block. All hypothesis
tests were conducted at the 0.05 level of signiﬁcance using two-sided tests.
Table 24 summarises the results of the three ASTs. In AST-1 and AST-3, no mortality occurred. In
AST-2, two birds died in the robenidine HCl treated group; one on the day before infection and one on
the day of infection.
Comparing the percentage of birds with 0 lesion scores (in small intestine and caecum) in the
different treatment groups, signiﬁcant differences were found between IUC and IT group only in AST-
1. OPGs were not affected by the coccidiostatic treatment. Higher body weight, higher daily weight
gain and improved feed to gain ratio were seen in all studies for the IT groups compared to IUC
groups. The difference was signiﬁcant in AST-1 for daily weight gain and feed to gain ratio, in AST-2
for body weight and daily weight gain and in AST-3 for feed to gain ratio.
Table 24: Results of anticoccidial sensitivity tests in turkeys
Tr.
group
Daily Feed
Intake (g)
Body
weight (g)
Daily
Weight
Gain (g)
Feed to
gain ratio
Total OPG
Lesion scores(1)
Lower small
intestine
Caecum
D14–20 D20 D14–20 D14–20 D20 D20
AST-1 UUC 55a 553a 36ab 1.51a 0b 93.3a 90.9a
IUC 48b 550a 33a 1.47a 236,157a 33.3b 9.4b
IT 51ab 575a 39b 1.30b 232,819a 86.7a 84.3a
AST-2 UUC 69a 448a 30a 2.31a 0b 100a 100a
IUC 68a 385b 21b 3.27b 113,585a 52.5b 93.8a
IT 74a 458a 28a 2.63ab 142,134a 46.6b 97.2a
D16–22 D22 D16–22 D16–22 D22 D22
AST-3 UUC 52a 507a 33a 1.56a 0b 43.3a 83.3a
IUC 49ab 469b 28b 1.78b 238,143a 43.3a 50.0a
IT 47b 477ab 29b 1.61a 212,687a 30.0a 63.4a
a,b,c: Means in a column within a study with different superscript are signiﬁcantly different (p ≤ 0.05).
(1): Percentage of birds without lesions (lesion score = 0).
45 AST-1: Technical dossier/Section IV/Annex IV.2.3. AST-2: Annex IV.2.4. AST-3: Annex IV.2.5.
46 AST-1: German ﬁeld isolate (06/2011), estimated dosage per bird: 53,600 E. meleagrimitis, 3,200 E. dispersa, 6,800 E.
adenoeides; AST-2: Polish ﬁeld isolate (Oct/2012), estimated dose per bird: 18,750 E. meleagrimitis, 250 E. dispersa, 6,000 E.
adenoeides; and AST-3: UK ﬁeld isolate (Jan/2013), estimated dosage per bird: 61,920 E. meleagrimitis, 2,160 E. dispersa
5,280 E. adenoeides.
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Conclusions of efﬁcacy in turkeys for fattening
The potential of 30 mg robenidine HCl/kg complete feed for turkeys to be efﬁcacious as
coccidiostat was shown in one ﬂoor pen study only. Two other ﬂoor pen studies could not be assessed
due to high not coccidiosis-related mortality. Since conclusions on the efﬁcacy of a coccidiostat require
three ﬂoor pen studies, no ﬁnal conclusion can be drawn.
In summary, only one AST showed a signiﬁcant coccidiostatic effect in turkeys, and that at the
high-dose proposed (36 mg robenidine HCl/kg feed).
3.3.3. Studies on the quality of the animal products where this is not the effect
claimed
The applicant made reference to the previous opinion of the FEEDAP Panel in which the effect of
robenidine HCl on the ﬂavour of broiler meat and tissues was assessed (EFSA, 2008a). The
Panel noted that off-ﬂavours were observed in edible tissues of chickens for fattening until 3 days after
withdrawal. In the absence of data on the impact of robenidine on the sensory properties of turkey
products, the FEEDAP Panel considered that chickens and turkeys should be similarly regarded.
3.3.4. Conclusions on efﬁcacy for the target species
Based on the results of three ﬂoor pen studies with 30 mg robenidine HCl/kg feed and three ASTs
with 36 mg robenidine HCl/kg feed, the FEEDAP Panel concludes that 36 mg robenidine HCl/kg
complete feed has the potential to effectively control coccidiosis of chickens for fattening under ﬁeld
conditions.
Since in turkeys for fattening, only one of the three submitted ﬂoor pen studies could be assessed
and only one of the three submitted ASTs indicated anticoccidial activity of robenidine HCl, the FEEDAP
Panel cannot conclude on the efﬁcacy of the additive in turkeys for fattening.
The existing 5-day withdrawal period to avoid off-ﬂavours in edible tissues should be maintained in
both chickens for fattening and turkeys for fattening.
3.4. Post-market monitoring
Field monitoring of Eimeria spp. resistance in chickens for fattening and turkeys for fattening to
robenidine HCl should be undertaken, preferably during the latter part of the period of authorisation.
4. Conclusions
The FEEDAP Panel concludes that the use of Robenz® 66G at the concentration of 36 mg
robenidine HCl/kg feed is safe for chickens for fattening with a margin of safety of approximately 2.5.
This conclusion is extrapolated to turkeys for fattening.
No interactions or incompatibilities are expected when robenidine HCl is used as a feed additive for
chickens and turkeys for fattening.
Robenidine is active against Gram-positive but not against Gram-negative bacteria. It is not
expected that the use of robenidine HCl as a feed additive would induce resistance or cross-resistance
to antimicrobials used in human and animal therapy.
The use of robenidine HCl from Robenz® 66G at the highest proposed level of 36 mg/kg complete
feed in chickens and turkeys for fattening is considered safe for the consumer. The existing MRLs for
both avian species are conﬁrmed.
Robenidine HCl is not a skin or eye irritant and not a skin sensitiser. Based on the low acute
inhalation toxicity and low exposure, the risk via inhalation is considered negligible.
The use of robenidine HCl from Robenz® 66G in feed for chickens for fattening and turkeys for
fattening up to 36 mg/kg complete feed does not pose a risk to either the terrestrial or the aquatic
compartment. A risk for bioaccumulation cannot be excluded. The risk for secondary poisoning is not
likely to occur.
The FEEDAP Panel concludes that 36 mg robenidine HCl/kg complete feed from Robenz® 66G has
the potential to effectively control coccidiosis of chicken for fattening under ﬁeld conditions.
The FEEDAP Panel cannot conclude on the efﬁcacy of robenidine HCl in turkeys for fattening.
The existing 5-day withdrawal period to avoid off-ﬂavours in edible tissues should be maintained in
both chickens for fattening and turkeys for fattening.
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Documentation provided to EFSA
1) Robenz® 66G for chickens for fattening and turkeys. October 2013. Submitted by Zoetis
Belgium SA.
2) Robenz® 66G for chickens for fattening and turkeys. Supplementary information. April 2015.
Submitted by Zoetis Belgium SA.
3) Robenz® 66G for chickens for fattening and turkeys. Supplementary information. June 2016.
Submitted by Zoetis Belgium SA.
4) Robenz® 66G for chickens for fattening and turkeys. Supplementary information. February
2017. Submitted by Zoetis Belgium SA.
5) Robenz® 66G for chickens for fattening and turkeys. Supplementary information. August
2017. Submitted by Zoetis Belgium SA.
6) Evaluation report of the European Union Reference Laboratory for Feed Additives on the
Methods of Analysis for Robenz® 66G.
7) Comments from Member States.
Chronology
Date Event
30/10/2013 Dossier received by EFSA
29/11/2013 Reception mandate from the European Commission
18/8/2014 Application validated by EFSA – Start of the scientiﬁc assessment
24/10/2014 Reception of the Evaluation report of the European Union Reference Laboratory for Feed Additives
30/10/2014 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended. Issues: characterisation, safety for target
species, safety for the consumer, safety for the environment and efﬁcacy
18/11/2014 Comments received from Member States
4/5/2015 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
29/6/2015 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended Issues: Safety for the target species
1/6/2016 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
18/7/2016 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended Issues: Safety for the target species, safety
for the environment and efﬁcacy
14/2/2017 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
27/2/2017 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended Issues: Efﬁcacy
30/8/2017 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
24/1/2019 Opinion adopted by the FEEDAP Panel. End of the Scientiﬁc assessment
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Abbreviations
ADI acceptable daily intake
ADME absorption, distribution, metabolism and excretion
AF assessment factor
ANOVA analysis of variance
CFU colony forming unit
CV coefﬁcient of variation
DITR Dietary intake of total residues
DT50 disappearance time 50 (the time within which the concentration of the test substance is
reduced by 50%)
DT90 disappearance time 90 (the time within which the concentration of the test substance is
reduced by 90%)
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EC50 median effective concentration
ErC50 median effective concentration which results in a 50% reduction in growth rate
EURL European Union Reference Laboratory
FEEDAP EFSA Panel on Additives and Products or Substances used in Animal Feed
GLM general linear models
GLMM general linear mixed model
GLP Good Laboratory Practice
HPLC high-performance liquid chromatography
Koc adsorption or desorption coefﬁcient corrected for soil organic carbon content
LC50 median lethal concentration
LOD limit if detection
log Kow octanol/water partition coefﬁcient
LOQ limit of quantiﬁcation
LSD least signiﬁcant difference
MRL maximum residue limit
NOEC no observed effect concentration
NOAEL no observed adverse effect level
NOEL no observed effect level
OECD Organisation for Economic Co-operation and Development
PEC predicted environmental concentration
PNEC predicted no effect concentration
SCAN Scientiﬁc Committee on Animal Nutrition
SD standard deviation
TRC total residue concentration
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Appendix A – Molecular formula of impurities in robenidine HCl
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Annex A – Executive Summary of the Evaluation Report of the European
Union Reference Laboratory for Feed Additives on the Methods of Analysis
for Robenz® 66G
Robenz® 66G is a feed additive initially authorized for rabbits for breading and chickens, rabbits
and turkeys for fattening as Cycostat 66G by Commission Regulation (EC) No 1800/2004, belonging to
the group “Coccidiostats and other medicinal substances” listed in Chapter I of Annex B of Directive
70/524/EEC. This regulation has been modiﬁed by Commission Regulations (EC) No 214/2009 and
No 1014/2013. In the current application an authorisation of an existing product under article 10 (2) of
the Regulation (EC) No 1831/2003 is requested. Robenz® 66G consists of 6.6% (w/w) of robenidine
hydrochloride (active substance), calcium lignosulphonate as binder and calcium sulphate dihydrate as
diluent/carrier. The Applicant proposed a concentration of robenidine in feedingstuffs ranging from 30
to 36 mg/kg. Furthermore the Applicant suggested Maximum Residue Limits (MRLs) in wet tissues
ranging from 200 to 1300 lg/kg for chicken for fattening and from 200 to 400 lg/kg for turkeys for
fattening, as already established by Commission Regulation (EC) No 214/2009.
For the quantiﬁcation of robenidine in feedingstuffs the Applicant submitted the ring-trial validated
Community method based on High Performance Liquid Chromatography coupled to Ultraviolet
detection (HPLC-UV). Furthermore the Applicant applied the Community method with minor
experimental modiﬁcations to the feed additive (Robenz® 66G) and premixtures and obtained similar
method performance characteristics. Based on the provided performance characteristics the EURL
recommends for ofﬁcial control the HPLC-UV method for the quantiﬁcation of robenidine in the feed
additive, premixtures and feedingstuffs.
For the quantiﬁcation of robenidine in tissues (chicken kidney and turkey skin/fat) the Applicant
submitted a method based on reverse phase High Performance Liquid Chromatography coupled to a
triple quadrupole mass spectrometer (RP-HPLC-MS/MS) in electrospray ionisation mode using matrix-
matched standards. This method was developed and validated according to Commission Decision
2002/657/EC by the European Union Reference Laboratory for Pharmacologically Active Substances
(BVL). The satisfactory results provided by the Applicant for kidney and skin/fat demonstrate the
applicability - and therefore extension of scope - of the BVL method to these two additional tissues.
Based on the performance characteristics presented the EURL recommends for ofﬁcial control the RP-
HPLC-MS/MS method - or any equivalent methods complying with the requirements set by Commission
Decision 2002/657/EC - for the determination of robenidine in chicken and turkey tissues.
Further testing or validation of the methods to be performed through the consortium of National
Reference Laboratories as speciﬁed by Article 10 (Commission Regulation (EC) No 378/2005) is not
considered necessary.
Robenz® 66G (robenidine hydrochloride) for chickens for fattening and turkeys for fattening
www.efsa.europa.eu/efsajournal 35 EFSA Journal 2019;17(3):5613
